Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by wofatson Jan 16, 2023 2:34pm
175 Views
Post# 35226207

Increase by country 2020 to 2021

Increase by country 2020 to 2021

2020
2021 Increase
Brazil 78.71 39.4% 97.20 39.9% +23.5%
Colombia 34.82 17.5% 43.52 17.9% +25%
Argentina 37.85 19% 42.96 17.6% +13.51%
Rest of Latin America 33.86 17% 40.95 16.8% +20.92%
Other 9.29 4.7% 11.15 4.6% +19.98%
Canada 5.00 2.5% 7.70 3.2% +54.15%

These increases in sales by country  from 20 to 21  were interesting .What will 22 be like?
i am looking forward to seeing what if any increases will be there from Latin America, as someone has been saying that everything is so bad there. When things get politically bad, don't people still get sick?
People dont need medicine in a bad political climate?
I am sure that some sales will be transacted . 
After the Last Financing ,Goodman Stated he had enough monies in the kitty to acomplish what needed to be done and not to expect something done quickly just to do something.
10 years since startup .I think 5 financings were done at higher valuations every time.7 years since the last financing. NO Extra DILUTION.  
It seems stocks only get noticed or investors are happy is when they finance .



<< Previous
Bullboard Posts
Next >>